Patents by Inventor Nina Wressnigg

Nina Wressnigg has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • SINGLE SHOT CHIKUNGUNYA VIRUS VACCINE
    Publication number: 20220313810
    Abstract: The present invention relates to a single-shot live attenuated vaccine against Chikungunya virus which is well-tolerated and induces long-lasting protective immunity in adult human subjects.
    Type: Application
    Filed: August 10, 2020
    Publication date: October 6, 2022
    Applicant: Valneva SE
    Inventors: Nina Wressnigg, Romana Hochreiter
  • Compositions comprising chimeric OSPA molecules and methods of use thereof
    Patent number: 9023367
    Abstract: The invention relates to the development of chimeric OspA molecules for use in a new Lyme vaccine. More specifically, the chimeric OspA molecules comprise the proximal portion from one OspA serotype, together with the distal portion from another OspA serotype, while retaining antigenic properties of both of the parent polypeptides. The chimeric OspA molecules are delivered alone or in combination to provide protection against a variety of Borrelia genospecies. The invention also provides methods for administering the chimeric OspA molecules to a subject in the prevention and treatment of Lyme disease or borreliosis.
    Type: Grant
    Filed: July 11, 2013
    Date of Patent: May 5, 2015
    Assignees: Baxter International Inc., Baxter Healthcare SA
    Inventors: P. Noel Barrett, Gerald Aichinger, Brian A. Crowe, Ian Livey, Nina Wressnigg
  • COMPOSITIONS COMPRISING CHIMERIC OSPA MOLECULES AND METHODS OF USE THEREOF
    Publication number: 20140030284
    Abstract: The invention relates to the development of chimeric OspA molecules for use in a new Lyme vaccine. More specifically, the chimeric OspA molecules comprise the proximal portion from one OspA serotype, together with the distal portion from another OspA serotype, while retaining antigenic properties of both of the parent polypeptides. The chimeric OspA molecules are delivered alone or in combination to provide protection against a variety of Borrelia genospecies. The invention also provides methods for administering the chimeric OspA molecules to a subject in the prevention and treatment of Lyme disease or borreliosis.
    Type: Application
    Filed: July 11, 2013
    Publication date: January 30, 2014
    Applicants: BAXTER HEALTHCARE SA, BAXTER INTERNATIONAL INC.
    Inventors: P. Noel Barrett, Gerald Aichinger, Brian A. Crowe, Ian Livey, Nina Wressnigg
  • Modified influenza virus
    Patent number: 8592196
    Abstract: The present invention provides an influenza B virus M gene with a modification of at least one nucleotide proximate to the N-terminus of the M gene, more specifically at any one of nucleotide positions 265 to 294 of the M gene. The present invention also provides an influenza B virus comprising the modified M gene, the use of the modified M gene for the preparation of a vaccine and methods for preparing the modified influenza virus.
    Type: Grant
    Filed: December 22, 2008
    Date of Patent: November 26, 2013
    Assignee: Baxter Healthcare SA
    Inventors: Christian Kittel, Nina Wressnigg
  • MODIFIED INFLUENZA VIRUS
    Publication number: 20100322970
    Abstract: The present invention provides an influenza B virus M gene with a modification of at least one nucleotide proximate to the N-terminus of the M gene, more specifically at any one of nucleotide positions 265 to 294 of the M gene as well as an influenza B virus comprising said modified M gene. Further, its use for the preparation of a vaccine and methods for preparing said modified influenza virus are disclosed.
    Type: Application
    Filed: December 22, 2008
    Publication date: December 23, 2010
    Inventors: Christian Kittel, Nina Wressnigg